Roche extends Spark offer again as regulatory review drags on
Add BT as a preferred source
[ZURICH] Roche extended its offer to buy Spark Therapeutics on Monday, this time until Oct 30, as US and British regulators continue to scrutinize the Swiss drugmaker's US$4.3 billion oft-delayed bid to swallow the US gene therapy specialist.
The terms and conditions remain unchanged for the deal, which analysts have said may be hung up on competition concerns over what a combination would mean for the very competitive market for hemophilia A treatments. Roche has declined to comment on what is holding back the US Federal Trade Commission from signing off on the transaction.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
High Court rejects bid to bring ST Engineering unit into trademark infringement suit over RSAF aircraft parts
Ex-Sakae director Ong Siew Kwee handed 10.5-year jail term for misappropriating S$15.8 million, lying in court
DBS sees choppy Q3 for STI as investors pivot from Singapore banks to listcos that are unlocking value
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
